A linked national study measured dispensing prevalence over a defined window. Its hypnotic category and broader psychotropic percentage should not be relabeled as benzodiazepine-only use.
The study included about 3.85 million older adults meeting census and dispensing criteria. Almost one-third received a psychotropic during August–October 2021. The reported benzodiazepine-and-Z-drug category was much narrower than that overall figure.
A twelve-month sensitivity analysis produced higher exposure prevalence, showing how the observation window changes what is counted.
One recorded dispensing qualified as use. Days supplied were unavailable, so the study could not establish continuous long-term treatment from that definition. Its demographic associations also were cross-sectional.
A group difference does not show that identity or social characteristics caused medication use, nor establish inappropriate care. The paper supports reviewing indications and access within their context. It cannot determine actual ingestion, degree of impairment, or dependence in an individual from one dispensing record or a national prevalence estimate.
Original analysis of the supplied journal article, identified as PMC12313767.